Clinical Trial Results: A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for the GVGH altSonflex1-2-3 vaccine targeting diarrhoea caused by Shigella, assessing safety and immune responses in adults, children, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea
• Shigellosis

Drugs mentioned

• altSonflex1-2-3 vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diarrhoea | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-22